Ignite Creation Date:
2024-05-06 @ 3:26 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02280785
Status:
COMPLETED
Last Update Posted:
2018-09-06
First Post:
2014-10-05
Brief Title:
Brentuximab Vedotin for RelapsedRefractory CD30-positive Non-Hodgkin Lymphomas
Sponsor:
Organization:
Samsung Medical Center